Blocking Appetite Hormone Receptor Builds Stronger Muscles and Fights Age-Related Loss
New research shows targeting ghrelin receptors improves muscle function and reduces sarcopenia in aging mice through better mitochondrial health.
Summary
Scientists discovered that blocking the ghrelin receptor (GHSR-1a) significantly improves muscle strength and endurance in aging mice. Ghrelin, an appetite hormone that increases with age, appears to contribute to muscle loss. Mice without this receptor showed 45% better running endurance, less muscle fatigue, and superior mitochondrial function compared to normal mice. The benefits included increased muscle fiber preservation, better energy production, and enhanced cellular cleanup processes. Researchers also tested a drug that blocks the same receptor and found similar improvements in both young and old mice, suggesting this approach could translate to human treatments for age-related muscle loss.
Detailed Summary
Researchers have identified a promising new approach to combat sarcopenia—the age-related loss of muscle mass and strength—by targeting the receptor for ghrelin, an appetite hormone that increases with aging. Published in Aging Cell, this study demonstrates how blocking ghrelin's effects can significantly improve muscle function and mitochondrial health in aging mice.
Mice genetically engineered to lack the ghrelin receptor (GHSR-1a) showed remarkable improvements in muscle performance as they aged. At 24 months, these mice could run nearly 30% longer than normal mice, and by 28 months, their endurance advantage increased to 45%. They also demonstrated superior muscle strength relative to body weight and experienced less muscle fatigue during electrical stimulation tests.
The underlying mechanism involves enhanced mitochondrial function—the cellular powerhouses responsible for energy production. Knockout mice maintained better mitochondrial DNA production, increased signals for creating new mitochondria, and improved cellular cleanup processes that remove damaged mitochondria. These changes were accompanied by preserved muscle fiber types that typically decline with aging.
To test clinical potential, researchers administered PF-5190457, a drug that blocks the ghrelin receptor, to both young and old mice for one month. The treatment replicated many benefits seen in knockout mice, including improved running performance and enhanced mitochondrial cleanup, while also reducing body weight and fat mass.
However, important limitations exist. Despite muscle improvements, the intervention didn't extend lifespan in mice. The effects, while significant, weren't complete cures for sarcopenia. Additionally, human translation remains uncertain, as mouse studies don't always predict human outcomes. Nevertheless, this research provides a compelling foundation for developing targeted therapies against age-related muscle decline.
Key Findings
- Blocking ghrelin receptors improved running endurance by 45% in aged mice
- Knockout mice showed better muscle strength and reduced fatigue during stimulation tests
- Treatment preserved mitochondrial function and enhanced cellular cleanup processes
- Pharmacological receptor blocking replicated benefits in both young and old mice
- Muscle improvements occurred without extending overall lifespan
Methodology
This is a research summary reporting on a peer-reviewed study published in Aging Cell, a reputable aging research journal. The evidence is based on controlled mouse experiments using both genetic knockout models and pharmacological interventions.
Study Limitations
The study was conducted only in mice, and results may not translate to humans. The intervention didn't improve lifespan despite muscle benefits, and the article appears incomplete, potentially missing important details about study limitations or adverse effects.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.